# EDGAR Filing Document

**Accession Number:** 0001795091
**File Stem:** 0001213900-26-016408
**Filing Date:** 2026-2
**Character Count:** 5151
**Document Hash:** ec552e919b877ca9ea6baf658afb69e9
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-26-016408.hdr.sgml**: 20260213

**ACCESSION NUMBER**: 0001213900-26-016408

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20260210

**ITEM INFORMATION**: Other Events

**FILED AS OF DATE**: 20260213

**DATE AS OF CHANGE**: 20260213

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** OS Therapies Inc
- **CENTRAL INDEX KEY:** 0001795091
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 825118368
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-42195
- **FILM NUMBER:** 26632692

**BUSINESS ADDRESS:**
- **STREET 1:** 15825 SHADY GROVE ROAD
- **STREET 2:** SUITE 135
- **CITY:** ROCKVILLE
- **STATE:** MD
- **ZIP:** 20850
- **BUSINESS PHONE:** 410-297-7793

**MAIL ADDRESS:**
- **STREET 1:** 15825 SHADY GROVE ROAD
- **STREET 2:** SUITE 135
- **CITY:** ROCKVILLE
- **STATE:** MD
- **ZIP:** 20850

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** OS THERAPIES Inc
- **DATE OF NAME CHANGE:** 20191125

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, DC 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the**

**Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): <u>February 10, 2026</u>

**OS THERAPIES INCORPORATED**

(Exact name of registrant as specified in its charter)

<u>Delaware</u> <u>001-42195</u> <u>82-5118368</u> <br> (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)

<u>115 Pullman Crossing Road, Suite 103 Grasonville, Maryland</u> <u>21638</u> <br> (Address of Principal Executive Offices) (Zip Code)

Registrant's telephone number, including area code: <u>(410)</u> 297-7793

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of Each Class** | **Trading Symbol(s)** | **Name of Each Exchange on Which Registered** |
| Common Stock, par value $0.001 per share | OSTX | NYSE American |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**CURRENT REPORT ON FORM 8-K**

**OS Therapies Incorporated**

**February 10, 2026**

**Item 8.01. Other Events.**

As previously announced, on January 10, 2026, OS Therapies Incorporated (the "Company") entered into inducement offer letter agreements with less than 10 accredited investors (the "Holders") that hold certain existing warrants of the Company to purchase up to an aggregate of 5,382,148 shares of the Company's common stock (the "Existing Warrants"), pursuant to which the Holders agreed to exercise for cash, or pre-fund for cash the exercise of, their Existing Warrants at a reduced exercise price of $1.40 per share (or $1.399 per share in the case of pre-funding) in consideration of the Company's agreement to issue new common stock purchase warrants to purchase up to an aggregate of 5,382,148 shares of the Company's common stock at an exercise price of $1.40 per share, subject to adjustment as provided therein.

On February 10, 2026, the Company, with the consent of the Company's warrant solicitation agent, extended the offering period, which was originally scheduled to expire at 11:59 p.m., Eastern time, on February 10, 2026, to 11:59 p.m., Eastern time, on March 2, 2026.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
|  | **OS THERAPIES INCORPORATED** | **OS THERAPIES INCORPORATED** | **OS THERAPIES INCORPORATED** |
| Dated: February 13, 2026 | By: | /s/ Paul A. Romness, MPH | /s/ Paul A. Romness, MPH |
|  |  | Name: | Paul A. Romness, MPH |
|  |  | Title: | President and Chief Executive Officer |

---